Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small and large molecule product candidates for immuno-inflammatory diseases. The company utilizes its proprietary KINect drug discovery platform to identify kinase inhibitors and advances biologics programs comprising monoclonal and multispecific antibodies. Key product candidates include bosakitug (ATI-045), an anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody, and ATI-2138, an oral covalent inhibitor of ITK and JAK3. The pipeline also includes ATI-052, a bispecific antibody targeting TSLP and IL-4Ra, and JAK-sparing ITK inhibitors such as ATI-9494. Aclaris holds exclusive global rights to bosakitug, excluding Greater China, which is licensed from Biosion, Inc. The company targets patients with atopic, respiratory, inflammatory, and immunologic diseases, including atopic dermatitis, severe asthma, and chronic rhinosinusitis with nasal polyps. Aclaris seeks to identify and consummate transactions with third-party partners to further develop, obtain marketing approval for, and commercialize its novel product candidates.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage aclaristx.com
Sector Healthcare IR page investor.aclaristx.com
Tags
immuno-inflammatory diseases, small molecule inhibitors, monoclonal antibodies, bispecific antibodies, kinase inhibitors, atopic dermatitis, respiratory diseases, drug discovery platform, clinical-stage, KINect, bosakitug, ATI-045, ATI-052, ATI-2138, ATI-9494, Biosion Inc.
Press page —

Metrics

Valuation  
Market cap $ 793.341M
Market cap (USD) $ 793.341M
P/E -9.07
PEG —
P/BV 4.76
P/S 123.94
P/OCF -10.55
P/FCF -10.53
Dividend yield —
Turnover / mcap —
Returns  
ROE -50.2%
ROI -76.7%
ROIC -67.6%
Profit margin -829.6%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 31
Quality score -76.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Revenue 7.826M 18.72M 31.249M 29.752M 6.761M 6.482M 4.227M 10.091M 1.683M — — —
Net profit -64.923M -132.065M -88.481M -86.908M -90.865M -51.015M -161.354M -132.738M -68.523M -48.079M -20.563M -8.517M
Free cash flow -47.224M -20.196M -79.634M -68.172M -52.442M -39.086M -98.058M -102.167M -55.898M -34.835M -20.876M -8.053M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Share price 3.01 2.48 1.05 15.75 14.54 6.47 1.89 7.39 24.66 27.14 26.94 —
Price performance 12m 0.21 1.36 -0.93 0.08 1.25 2.43 -0.74 -0.7 -0.09 0.01 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 481,000 4.86M 704,000 772,000 623,000 484,000 298,000 318,000 —
↳ YoY growth +910.6% -85.5% +9.7% -19.3% -22.3% -38.4% +6.7%
↳ 5y CAGR +0.1% -42.8% -14.7%
Lease liabilities (USD) — — — 4.07M 3.5M 2.89M 2.25M 3.5M 2.6M 2.12M
Cash and deposits (USD) 30.2M 20.2M 57M 35.9M 22.1M 27.3M 45.3M 39.9M 24.6M 20M
Intangible assets (USD) — 7.35M 73M 7.2M 7.12M 7.05M 6.97M 269,000 — —
Cash flow detail
Operating cash flow (USD) -34.6M -54.7M -101M -96.4M -38.6M -52.1M -67.6M -78.3M -20.1M -47.1M
Purchases of property, plant and equipment (USD) -232,000 -1.24M -1.36M -1.61M -453,000 -308,000 -605,000 -1.31M -121,000 -111,000
Purchases of intangible assets (USD) — — — — — — — — -35.8M —
Change in receivables (cash effect) (USD) — — -4.38M -809,000 4.9M 149,000 139,000 186,000 -20,000 —
Change in inventories (cash effect) (USD) — — 102,000 605,000 — — — — — —
Change in payables (cash effect) (USD) 1.81M 4.56M 6.96M -3.16M -5.22M 3.66M 368,000 -1.47M -4.19M 8.45M
Share-based compensation (USD) 6.1M 14.4M 20.1M 16.2M 11.2M 14.1M 15M 20.5M 10.9M 12.4M
Operating cash flow before change in receivables (USD) — — -96.4M -95.6M -43.5M -52.3M -67.7M -78.5M -20.1M —
Free cash flow (OCF - PPE - intangibles) (USD) -34.8M -55.9M -102M -98.1M -39.1M -52.4M -68.2M -79.6M -56M -47.2M
Income detail
Research and development expense (USD) 33.5M 39.8M 63M 64.9M 31.7M 43.8M 77.8M 98.4M 33.6M 52.6M
↳ 5y CAGR +78.4% +58.4% +15.6% +5.5% +14.4% +9.3% -12.3% +10.7%
Total comprehensive income (USD) -48.2M -68.5M -133M -161M -51M -91M -87.6M -87.7M -132M -64.4M
Comprehensive income to owners (USD) -48.2M -68.5M -133M -161M -51M -91M -87.6M -87.7M -132M -64.4M
Reported Mar 15, 2017 Mar 12, 2018 Mar 18, 2019 Feb 25, 2020 Feb 25, 2021 Feb 24, 2022 Feb 23, 2023 Feb 27, 2024 Feb 27, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

- The ADMIRATION Trial Did Not Achieve its Primary Endpoint of Percent Change in Eczema Area and Severity Index (EASI) Score from Baseline at Week 24 -

- Aclaris Remains Focused on Prioritizing the Development of its Oral Kinase (ITK) Inhibitors and Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 -

WAYNE, Pa., November 16, 2026 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced top line results from the Phase 2 ADMIRATION trial that evaluated the efficacy and safety of bosakitug (ATI-045), a humanized anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody, in patients with moderate-to-severe atopic dermatitis. The trial did not achieve the primary or secondary endpoints; however, pharmacodynamic (PD) results showed robust target engagement of TSLP and downregulation of biomarkers related to immune activation including Th1, Th2, and Th17. Bosakitug was generally well tolerated in this trial.

November 5, 2026

  • Initiation of Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus Expected in Fourth Quarter of 2026 -

  • Timeline Reaffirmed for Top Line Results from Phase 2 ADMIRATION Trial of Bosakitug (ATI-045) in Atopic Dermatitis (AD) -

  • Positive Primary Analysis Results Announced from Phase 1b Proof-of-Concept (POC) Trials of ATI-052 in AD and Asthma -

  • Strong Cash Runway Expected to Enable Development of Pipeline Through the First Half of 2029 -

WAYNE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2026 and provided a corporate and clinical update.

“Aclaris is developing unique product candidates designed to provide improved therapeutic options across a variety of inflammatory disorders with the goal of raising the efficacy ceiling, and our recent progress reflects continued execution toward that objective,” stated Dr. Neal Walker, Chief Executive Officer and Chair of the Board of Directors of Aclaris. “We recently announced strongly positive primary analysis results from our Phase 1b POC trials with ATI-052 in AD and asthma; we look forward to starting a Phase 2b trial in eosinophilic esophagitis early next year. Beyond that, we have a series of expected clinical and regulatory milestones throughout the rest of 2026 and 2027, including Phase 2 results in AD from bosakitug and the start of the Phase 2b trial of our oral ITK/JAK3 inhibitor modzatinib in lichen planus, both in the coming few weeks.”

Third Quarter 2026 Highlights, Recent Updates and Upcoming Catalysts

Pipeline:

Biologics: Antibody Franchise

  • Positive Primary Analysis Results Demonstrated Rapid Improvement in Skin and Itch in Phase 1b POC Trial of Investigational Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052 in Severe AD: Patients treated with ATI-052 experienced a 45% placebo-adjusted mean change in EASI score from baseline at week 8 with durable responses for the subset of patients with available data observed through week 16 (follow up ongoing) and a 78% placebo-adjusted EASI-50 at week 8. Patients who received ATI-052 experienced a 43% placebo-adjusted mean improvement in itch (PP-NRS) at week 8. ATI-052 was well tolerated and demonstrated a favorable safety profile. No conjunctivitis was observed. (press release here)

  • **Normalization of Lesional Skin Toward Baseline with ATI-052 Observed in Pharmacodynamic Results in AD:**Marked normalization observed in the lesional skin proteome at week 8 in patients receiving ATI-052, with immune protein expression resembling that of non-lesional skin. ATI-052 induced a broad pathway downregulation, with modulation across multiple inflammatory pathways, Th1, Th2 and Th17/Th22, fibrosis/ECM remodeling, and itch-associated molecular pathways. (press release here)

  • Positive Primary Analysis Results Showed Rapid Improvement in Airway Inflammation and Lung Function in Phase 1b POC Trials of ATI-052 in Asthma: Following a single dose of ATI-052, patients experienced a rapid 59% mean absolute reduction in fractional exhaled nitric oxide (FeNO) (45 ppb) only 15 days after administration and a 40% reduction at day 29. Patients receiving ATI-052 experienced a placebo adjusted and absolute 200 ml improvement in Forced Expiratory Volume in 1 Second (FEV1) at day 15. Safety and tolerability were consistent with that of the Phase 1b AD POC trial, including no observations of conjunctivitis. (press release here)

  • **Aclaris to Prioritize Development of ATI-052 in Eosinophilic Esophagitis (EoE):**Consistent with its development strategy and capital management discipline, Aclaris intends to prioritize Phase 2b development of ATI-052 initially in EoE, where the Company believes ATI-052 is mechanistically well-matched. The Company expects to complete its assessment of an additional Phase 2b indication shortly, likely either AD or asthma.

  • **Readout of Top Line Results from Phase 2 Trial of Investigational Anti-TSLP Monoclonal Antibody Bosakitug Expected in the Fourth Quarter 2026:**The randomized, double-blind, placebo-controlled Phase 2 ADMIRATION trial is evaluating the efficacy and safety of bosakitug in 109 patients with moderate-to-severe atopic dermatitis.

Kinase Inhibitors: ITK Franchise

  • Initiation of Phase 2b Clinical Trial in Lichen Planus for Investigational Oral ITK/JAK3 Inhibitor Modzatinib Expected in the Fourth Quarter of 2026: Startup activities are ongoing with first site activation expected in November 2026 for this Phase 2b trial in lichen planus, an unaddressed chronic, inflammatory, CD8-driven interface dermatitis. There are currently no approved therapies in this indication.

  • **Filing of Investigational New Drug (IND) Application for Investigational Dual Inhibitor of ITK and TXK ATI-9494 On Track for Fourth Quarter 2026:**ATI-9494 has demonstrated potent blockade of Th1 and Th2 responses, a prolonged half-life, and high potency against ITK, potentially enabling low drug burden, dosing flexibility, and once daily administration across a broad range of disease indications.

Financial Results

Liquidity and Capital Resources

As of September 30, 2026, Aclaris had cash, cash equivalents and marketable securities of $204.6 million compared to $151.4 million as of December 31, 2025. During October 2026, the Company sold 7.8 million shares of its common stock and issued pre-funded warrants to purchase 6.5 million shares of common stock for aggregate gross proceeds of $50.0 million, pursuant to the Company’s underwriting agreement with Leerink Partners LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co.

Taking into account the net proceeds from the October offering, the Company believes that its cash, cash equivalents and marketable securities will be sufficient to fund its operations through the first half of 2029, without giving effect to any potential business development transactions or additional financing activities.

Third Quarter 2026 and Year-to-Date 2026

Net loss was $18.5 million for the third quarter of 2026 compared to $14.6 million for the third quarter of 2025. Net loss was $59.8 million for the nine months ended September 30, 2026 compared to $45.1 million for the nine months ended September 30, 2025.

Total revenue was $1.5 million for the third quarter of 2026 compared to $3.3 million for the third quarter of 2025. Total revenue was $5.1 million for the nine months ended September 30, 2026 compared to $6.5 million for the nine months ended September 30, 2025. The decreases were primarily driven by a sales milestone achieved under the Sun Pharma license agreement during the quarter and nine months ended September 30, 2025.

Research and development (R&D) expenses were $16.1 million and $49.8 million for the quarter and nine months ended September 30, 2026, respectively, compared to $13.0 million and $36.1 million for the corresponding prior year periods. The increases were primarily driven by expenses related to ATI-052, including product candidate manufacturing costs and clinical development expenses associated with Phase 1b programs in AD and asthma, as well as product candidate manufacturing costs and preclinical development expenses for ATI-9494.

General and administrative (G&A) expenses were $6.0 million and $18.8 million for the quarter and nine months ended September 30, 2026, respectively, compared to $4.9 million and $16.4 million for the prior year periods. The increases were primarily due to an increase in professional and legal expenses as well as personnel and stock-based compensation expenses.

Revaluation of contingent consideration resulted in a $0.6 million gain for the quarter ended September 30, 2026 compared to a $0.1 million charge for the prior year period, primarily due to higher discount rates and changes in estimated sales levels during the quarter ended September 30, 2026. For the nine months ended September 30, 2026, revaluation of contingent consideration resulted in a $0.3 million gain compared to a $1.9 million charge for the prior year period, primarily due to changes to the probability of success for certain product candidates during the nine months ended September 30, 2025.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The Company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations. These forward-looking statements include expectations regarding its plans for its development programs for bosakitug (ATI-045), ATI-052, modzatinib (ATI-2138), and ATI-9494, including the timing of reporting top line results from its Phase 2 trial of bosakitug in AD, the clinical development plans for ATI-052 including its intention to prioritize EoE and the timing to initiate a Phase 2b trial in EoE, and the timing to initiate a Phase 2b trial in lichen planus with modzatinib, the timing to file an IND for ATI-9494, the potential of ATI-9494 to enable low drug burden, dosing flexibility, and once daily administration across a broad range of disease indications, the therapeutic potential of its product candidates including the potential for such candidates to be best-in-class, and the sufficiency of its cash, cash equivalents and marketable securities to fund its operations through the first half of 2029. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of preclinical and clinical studies, risks associated with interim, top line and preliminary data, Aclaris’ reliance on third parties over which it may not always have full control, Aclaris’ ability to enter into strategic partnerships on commercially reasonable terms, the uncertainty regarding the macroeconomic environment and other risks and uncertainties that are described in the “Risk Factors” section of Aclaris’ Annual Report on Form 10-K for the year ended December 31, 2025, and other filings Aclaris makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the “SEC Filings” page of the “Investors” section of Aclaris’ website at www.aclaristx.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Aclaris Therapeutics Contacts:

Kevin Balthaser Chief Financial Officer (484) 329-2178 [email protected]

Will Roberts Senior Vice President Corporate Communications and Investor Relations (484) 329-2125 [email protected]

| Aclaris Therapeutics, Inc. Condensed Consolidated Statements of Operations (unaudited, in thousands, except share and per share data) |

| | Three Months Ended | | Nine Months Ended |

| | September 30, | | September 30, |

| | 2026 | | | 2025 | | | 2026 | | | 2025 | |

| | | | | | | | | | | | |

| Revenues: | | | | | | | | | | | |

| Contract research | $ | 300 | | | $ | 485 | | | $ | 1,193 | | | $ | 1,372 | |

| Licensing | | 1,181 | | | | 2,814 | | | | 3,913 | | | | 5,159 | |

| Total revenue | | 1,481 | | | | 3,299 | | | | 5,106 | | | | 6,531 | |

| | | | | | | | | | | | |

| Costs and expenses: | | | | | | | | | | | |

| Cost of revenue(1) | | 189 | | | | 538 | | | | 802 | | | | 1,559 | |

| Research and development(1) | | 16,066 | | | | 13,028 | | | | 49,789 | | | | 36,061 | |

| General and administrative(1) | | 6,038 | | | | 4,871 | | | | 18,829 | | | | 16,396 | |

| Licensing | | 1,132 | | | | 1,911 | | | | 3,760 | | | | 4,256 | |

| Revaluation of contingent consideration | | (600 | ) | | | 100 | | | | (300 | ) | | | 1,900 | |

| Total costs and expenses | | 22,825 | | | | 20,448 | | | | 72,880 | | | | 60,172 | |

| Loss from operations | | (21,344 | ) | | | (17,149 | ) | | | (67,774 | ) | | | (53,641 | ) |

| | | | | | | | | | | | |

| Other income: | | | | | | | | | | | |

| Interest income | | 1,849 | | | | 1,819 | | | | 5,124 | | | | 6,003 | |

| Non-cash royalty income | | 985 | | | | 716 | | | | 2,811 | | | | 2,510 | |

| Total other income | | 2,834 | | | | 2,535 | | | | 7,935 | | | | 8,513 | |

| Net loss | $ | (18,510 | ) | | $ | (14,614 | ) | | $ | (59,839 | ) | | $ | (45,128 | ) |

| Net loss per share, basic and diluted | $ | (0.12 | ) | | $ | (0.12 | ) | | $ | (0.43 | ) | | $ | (0.37 | ) |

| Weighted average common shares outstanding, basic and diluted | | 149,449,067 | | | | 122,619,311 | | | | 140,407,589 | | | | 122,531,032 | |

| | | | | | | | | | | | |

| (1) Amounts include stock-based compensation expense as follows: | | | | | | | | | | | |

| Cost of revenue | $ | 4 | | | $ | 191 | | | $ | 19 | | | $ | 600 | |

| Research and development | | 979 | | | | 964 | | | | 2,925 | | | | 3,255 | |

| General and administrative | | 2,036 | | | | 1,705 | | | | 5,945 | | | | 5,603 | |

| Total stock-based compensation expense | $ | 3,019 | | | $ | 2,860 | | | $ | 8,889 | | | $ | 9,458 | |

| Aclaris Therapeutics, Inc. Selected Consolidated Balance Sheet Data (unaudited, in thousands, except share data) |

| | | September 30, | | December 31, |

| | | 2026 | | 2025 |

| | | | | | | |

| Cash, cash equivalents and marketable securities | | $ | 204,607 | | $ | 151,363 |

| Total assets | | $ | 216,157 | | $ | 160,460 |

| Total current liabilities | | $ | 24,222 | | $ | 28,645 |

| Total liabilities | | $ | 49,358 | | $ | 57,378 |

| Total stockholders' equity | | $ | 166,799 | | $ | 103,082 |

| Common stock outstanding | | | 150,825,196 | | | 120,499,433 |

| Aclaris Therapeutics, Inc. Selected Consolidated Cash Flow Data (unaudited, in thousands) |

| | | Nine Months Ended |

| | | September 30, |

| | | 2026 | | | 2025 | |

| | | | | | | |

| Net loss | | $ | (59,839 | ) | | $ | (45,128 | ) |

| Depreciation and amortization | | | 309 | | | | 352 | |

| Stock-based compensation expense | | | 8,889 | | | | 9,458 | |

| Revaluation of contingent consideration | | | (300 | ) | | | 1,900 | |

| Changes in operating assets and liabilities | | | (11,135 | ) | | | (564 | ) |

| Net cash used in operating activities | | $ | (62,076 | ) | | $ | (33,982 | ) |

Primary Logo

Source: Aclaris Therapeutics, Inc.

On October 27, 2026, Aclaris Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co., as representatives of the underwriters (the “Underwriters”) listed therein, to issue and sell 7,785,714 shares of common stock of the Company, par value $0.00001 per share (“Common Stock”) and pre-funded warrants to purchase 6,500,000 shares of Common Stock (the “Pre-Funded Warrants”), in an underwritten offering pursuant to an effective registration statement on Form S-3 (File No. 333-298084) and a related prospectus and prospectus supplement, in each case filed with the Securities and Exchange Commission (the “Offering”). The offering price is $3.50 per share of Common Stock and $3.49999 per Pre-Funded Warrant. The Company estimates that the net proceeds from the Offering will be approximately $46.7 million, after deducting underwriting discounts and commissions and estimated offering expenses. The closing of the Offering is expected to occur on October 28, 2026, subject to customary closing conditions.

Prompts

Aclaris Therapeutics, Inc. (ticker ACRS), listed in United States.

ETFs Holding Aclaris Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
FSEG 0.14% 1,471 $ 7,781.59 Jun 30, 2026
VFMO 0.10% 321,480 $ 1.945M Aug 31, 2026
FSEV 0.08% 1,050 $ 5,554.50 Jun 30, 2026
RESM 0.03% 196 $ 1,036.84 Jun 30, 2026
FESM 0.02% 240,831 $ 1.274M Jun 30, 2026
DFAS 0.00% 187,373 $ 749.492K Nov 12, 2026
DFAU 0.00% 26,214 $ 104.856K Nov 12, 2026
DCOR 0.00% 36,504 $ 146.016K Nov 12, 2026
DFAC 0.00% 51,502 $ 206.008K Nov 12, 2026
DXUV 0.00% 404 $ 1,616.00 Nov 12, 2026